| 张娟,赵娜.第二代抗精神病药物治疗对精神疾病儿童体质量及代谢的影响[J].安徽医药,2017,21(11):2061-2065. |
| 第二代抗精神病药物治疗对精神疾病儿童体质量及代谢的影响 |
| Effects of second-generation antipsychotic treatment in children with mental disorders on risk of obesity and metabolic dysregulation |
| 投稿时间：2016-09-14 |
| DOI： |
| 中文关键词: 第二代抗精神药物 肥胖 代谢综合征 儿童精神疾病 |
| 英文关键词: Second-generation antipsychotic Obesity Metabolic dysregulation Mentaldisorders |
| 基金项目: |
|
| 摘要点击次数: 1846 |
| 全文下载次数: 612 |
| 中文摘要: |
| 目的 探讨利培酮或喹硫平长期治疗儿童精神疾病后,对肥胖及相关代谢失调的影响。方法 选取年龄2～18岁的具有精神类疾病的患者130例作为研究对象,所有患者治疗前均未服用过第二代抗精神药物(SGA),采用自然年度纵向调查法,研究分析了患儿的身体质量指标、生化指标、代谢参数。在12个月的研究周期内,共46例患儿(利培酮组25例,喹硫平组21例)的资料用于分析。结果 SGA治疗12个月后,患儿的体质量显著增加,利培酮组平均增加10.6(7.8～13.6) kg,喹硫平组平均增加9.5(6.3～12.7) kg,两组比较差异有统计学意义(P＜0.05)。同时,两组患儿的体质量指数Z(BMI z)评分也显著增高,儿童患超重或者肥胖的发生率也显著增加。快速血糖平均水平及高密度脂蛋白与总胆固醇比值明显增高,增高量分别为0.24(0.04-0.43) mmol·L-1和0.49(0.16～0.81) mmol·L-1。结论 儿童抗精神药物治疗12个月期间,儿童腰围显著增加、血脂指标异常,故儿童肥胖及代谢失调的风险显著升高。这一研究结果,对早期发现及代谢副作用治疗的有序检测具有重要意义。 |
| 英文摘要: |
| Objective To determine the risk of developing obesity and related metabolic complications in children following long-term treatment with risperidone or quetiapine. Methods One hundred and thirty patients aged 2 to 18 years with mental disorders were included.And all patients were not taken second-generation antipsychotic drugs.The study design was a 1-year naturalistic prospective longitudinal study.The body mass index,biochemical index and metabolic parameter of the children were studied and analyzed at baseline and months 6 and 12.Data of 46 participants(25 treated with risperidone and 21 treated with quetiapine) who completed 12-month monitoring were analyzed. Results After 12 months of second-generation antipsychotics(SGA) treatment,mean weight increased significantly by 10.6(7.8-13.6) kg for risperidone and 9.5(6.3-12.7) kg for quetiapine(P＜0.05).And body mass index z score(BMI z) also increased significantly in both groups(P＜0.05).There was a high incidence of children becoming overweight or obese.The mean levels of fasting glucose and ratio of total cholesterol to high-density lipoprotein cholesterol increased significantly by 0.24(0.03- 0.42) mmol·L-1and 0.49(0.15-0.81) mmol·L-1,respectively. Conclusions Children treated with risperidone or quetiapine have significant risks in developing obesity,elevated waist circumference,and dyslipidemia during 12 months of treatment.These data emphasize the importance of regular monitoring for early identification and treatment of metabolic side effects. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
